Tags Archive Navigation
icon
-
Media ReleaseNovartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
-
Media ReleaseNovartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media ReleaseNovartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-
Media ReleaseNovartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
-
Media ReleaseNovartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
-
Media ReleaseNovartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media ReleaseTV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
-
Media ReleaseRelapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media ReleaseNovartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Pagination
- ‹ Previous page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- …
- 49
- › Next page